![]() |
市场调查报告书
商品编码
1827706
2025年全球骨骼生长刺激器市场报告Bone Growth Stimulator Global Market Report 2025 |
近年来,骨骼生长刺激器市场规模强劲成长,从2024年的16.5亿美元增加到2025年的18亿美元,复合年增长率达9.2%。预测期内的成长归因于人口老化、整形外科疾病盛行率上升、人们对非侵入性治疗的认识不断提高、医疗保健可及性的扩大、报销政策的优惠、对微创解决方案的需求不断增长以及整形外科手术的普及率不断提高。
预计未来几年骨骼生长刺激器市场规模将快速成长,到2029年将达到26.5亿美元,复合年增长率为10.1%。预测期内的成长可归因于社会意识的提高、再生医学的普及、医疗基础设施的投资、用途和适应症的拓展以及支持性医疗政策。预测期内的主要趋势包括再生医学、3D列印技术的使用、无线和物联网技术在远端患者监护的应用、以患者为中心的护理以及远端医疗应用的日益普及。
骨骼生长刺激器 (BGS) 是一种旨在促进骨折后骨骼自然癒合的装置。 BGS 的主要作用是将能量输送到癒合中的骨骼表面,这可以透过脉衝电磁场或超音波技术实现。在脉衝电磁场中,BGS 会吸引带相反电荷的骨端,刺激新骨生长和融合,最终加速癒合过程。骨骼生长刺激器透过向骨折或癒合部位施加超音波或电流来辅助难以癒合的骨骼癒合。
骨骼生长刺激器 (BGS) 的主要类型包括骨生长刺激器、骨形态蛋白 (BMP) 和富血小板血浆疗法。骨生长刺激器可以植入体内,也可以透过绑带进行外部固定,从而加快骨折癒合速度并缩短癒合时间。这些装置可用于治疗骨折、脊椎融合、骨形成、关节重建和椎间滑脱。 BGS 的主要终端使用者包括医院、门诊手术中心 (ASC)、专科诊所和居家医疗。
2025年春季美国大幅提高关税及其引发的贸易摩擦对医疗设备产业产生了重大影响,尤其对用于诊断影像设备的进口零件、手术用不銹钢和一次性塑胶製品产生了重大影响。由于医院和诊所抵制涨价,製造商面临利润压力。监管挑战使情况更加复杂,因为由于关税而更换供应商通常需要重新认证医疗设备,导致市场进入延迟。为此,企业正在透过双重采购关键零件、增加标准化产品的国内生产以及加快研发更具成本效益的材料来降低风险。
本研究报告是商业研究公司(The Business Research Company)新报告系列的一部分,该系列提供骨骼生长刺激器市场统计数据,包括全球市场规模、各地区市场份额、竞争对手的骨骼生长刺激器市场份额、详细的骨骼生长刺激器细分市场、市场趋势和机会,以及在骨骼生长刺激器行业取得成功所需的其他数据。这份骨骼生长刺激器市场研究报告对该行业的现状和未来趋势进行了详细分析,提供了所有必要的完整观点。
未来五年的预测成长率为10.1%,较我们先前对该市场的预测略有下降0.1%。下降主要源自于美国与其他国家之间关税的影响。这可能会直接影响美国,因为美国对来自德国和以色列等关键地区的脉衝电磁场发生器和生物相容性电极阵列征收关税,从而导致骨折患者的治疗成本上升,非侵入性治疗工具的供应减少。由于互惠关税以及贸易紧张局势和限制加剧对全球经济和贸易的负面影响,这种影响也将更加广泛地显现。
骨骼生长刺激器市场预计将经历显着成长,主要原因是骨折发生率的上升。老龄化、饮食和慢性疾病等因素会削弱骨骼,使其更容易骨折。过度使用和重复性运动也会导致骨折。 2022 年 5 月,美国生技公司安进 (Amgen) 报告称,骨质疏鬆症每年在美国导致约 150 万人骨折,相关费用达 190 亿美元。此外,预计从 2018 年到 2040 年,骨质疏鬆性骨折的数量每年将增加 68%,达到 320 万人。骨折发生率的上升预计将成为推动骨骼生长刺激器市场成长的主要因素。
运动伤害的增加也推动了骨骼生长刺激器市场的成长。运动伤害会影响身体的各个部位,包括骨骼、肌肉、韧带和肌腱,通常需要介入以促进骨骼修復和復原。骨骼生长刺激器在促进骨骼修復、组织生长和运动伤害的整体癒合方面发挥关键作用。美国国家安全委员会于2022年报告称,2021年运动和休閒伤害将增加20%,2022年将再增加12%。运动伤害的增加趋势正在推动骨骼生长刺激器市场的扩张。
技术进步是骨骼生长刺激器市场的一大趋势,电骨生长刺激 (EBGS) 等创新方法日益受到关注。这种独特的方法旨在促进癒合并提高癒合成功率。 EBGS 设备的广泛采用和不断增长的经验已导致刺激范例和临床结果取得重大进展。例如,2022 年 5 月,美国脊椎、整形外科和骨骼发育解决方案製造商 Orthofix Medical Inc. 的 AccelStim 骨癒合治疗 III 类设备获得了美国食品药物管理局(FDA) 的上市前核准。 AccelStim 设备利用低强度脉衝超音波(LIPUS),为新骨折和癒合骨折(不癒合)提供了一种非手术治疗选择,并促进骨骼的自然癒合过程。
骨骼生长刺激器市场的主要企业正在优先考虑创新产品的核准,正如 ActaStim-S 脊椎融合骨骼生长刺激器系统的专利核准所示。该系统是一种非侵入性设备,旨在刺激脊椎融合手术后的骨骼修復和融合。显着特点包括无线设计和用户友好的行动应用程式。它已获得美国食品药物管理局(FDA) 的核准,可用于脊椎融合手术后使用或治疗先前手术失败的融合。 2022 年 8 月,美国製药和生物技术公司 TheraGen 宣布已成功获得其突破性 ActaStim-S脊椎融合系统的美国专利。 ActaStim-S 是一种突破性的脊椎融合刺激器,它将临床验证的治疗刺激与现代设计和数据丰富的数位健康平台相结合。这种方法不仅可以加速癒合过程,还可以在关键的术后融合阶段促进患者的依从性、参与度以及与医疗保健专业人员的知情沟通。
2022年11月,总部位于瑞典、生产先进不銹钢和特种合金等高附加价值产品的製造商Alleima收购了ENDOSMART医疗技术有限公司(ENDOSMART Gesellschaft fur Medizintechnik mbH),收购金额未揭露。此次收购旨在巩固Alleima的市场地位,拓宽其产品范围,并增强其在高性能材料方面的能力。 ENDOSMART医疗技术有限公司是一家专门生产医疗设备和零件的德国公司。
骨骼生长刺激器市场的主要企业包括 Arthrex Inc.、DJO Global Inc.、Stryker Corporation、Bioventus LLC、Zimmer Biomet Holdings Inc.、3M Company、Becton Dickinson and Company、Cognionics Inc.、ConMed Corporation、The Cooper Companies Inc.、DycorpMedix、Koninklijke Corporation Philips. Inc.、Ossatec Benelux BV、BTT Health GmbH、Stimulate Health Inc.、ZimVie Inc.、Enovis Inc.、DePuy Synthes Inc.、Smith & Nephew plc、BioTek Instruments Inc.、BioMimetic Therapeutics Inc、Cerament、Cook日 Inc. AG、NuVasive Inc. OrthoPediatrics Corp.、RTI Surgical Holdings Inc. 和 Wright Medical Group NV。
2024年,北美是骨骼生长刺激器市场最大的地区。预计亚太地区将成为预测期内成长最快的地区。骨骼生长刺激器市场报告涵盖的地区包括亚太地区、西欧、中欧和东欧、北美、南美以及中东和非洲。
骨骼生长刺激器市场报告涉及的国家有澳洲、巴西、中国、法国、德国、印度、印尼、日本、俄罗斯、韩国、英国和美国。
骨骼生长刺激器市场涵盖电动和超音波骨骼生长刺激器的销售。该市场的价值指的是“出厂价”,即产品製造商或生产商销售给其他营业单位(包括下游製造商、批发商、经销商和零售商)或直接销售给最终客户的商品价值。该市场中的商品价值还包括产品製造商提供的任何相关服务。
A bone growth stimulator (BGS) is a device designed to enhance the natural fusion of bones following a fracture. The primary goal of BGS is to deliver increased energy to the healing bone surface, achieved through either pulsed electromagnetic or ultrasound methods. In the case of pulsed electromagnetic fields, the BGS attracts the oppositely charged ends of the bones, stimulating new bone growth and fusion, ultimately promoting the healing process. Bone growth stimulators are employed to aid in bone healing for challenging fractures or fusions by applying ultrasonic or electrical current to the fracture or fusion site.
The main types of bone growth stimulators (BGS) include bone growth stimulation devices, bone morphogenetic proteins (BMP), and platelet-rich plasma (PRP) therapy. Bone growth stimulation devices can be either implanted internally or worn externally using straps to secure them in place, enhancing the rate and shortening the time required for fracture healing. These devices find application in the treatment of fractures, spinal fusion, osteogenesis, arthrodesis treatment, and spondylolisthesis. The primary end-use sectors for BGS include hospitals and ambulatory surgical centers (ASCs), specialty clinics, and home care.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.
The bone growth stimulators market research report is one of a series of new reports from The Business Research Company that provides bone growth stimulators market statistics, including bone growth stimulators industry global market size, regional shares, competitors with a bone growth stimulators market share, detailed bone growth stimulators market segments, market trends and opportunities, and any further data you may need to thrive in the bone growth stimulators industry. This bone growth stimulators market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The bone growth stimulator market size has grown strongly in recent years. It will grow from $1.65 billion in 2024 to $1.8 billion in 2025 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to aging population and orthopedic conditions, increasing awareness of non-invasive treatments, expansion of healthcare access, favorable reimbursement policies, increased demand for minimally invasive solutions, and increased orthopedic surgery prevalence.
The bone growth stimulator market size is expected to see rapid growth in the next few years. It will grow to $2.65 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to enhanced public awareness, regenerative medicine adoption, healthcare infrastructure investments, expanding applications and indications, and supportive healthcare policies. Major trends in the forecast period include regenerative medicine, the use of 3D printing technology, incorporating wireless and iot technologies for remote patient monitoring, patient-centric care, and increasing utilization of telemedicine.
The forecast of 10.1% growth over the next five years indicates a slight reduction of 0.1% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through tariffs on pulsed electromagnetic field generators and biocompatible electrode arrays, sourced from key regions such as Germany and Israel, which could lead to higher treatment costs for fracture patients and reduced availability of non-invasive healing devices.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The bone growth stimulators market is expected to experience significant growth, primarily driven by the increasing number of bone fractures. Factors such as age, dietary habits, and chronic disorders can weaken bones, making them more susceptible to fractures. Overuse or repetitive motions can also contribute to bone fractures. In May 2022, Amgen, a U.S.-based biotechnology company, reported that osteoporosis leads to approximately 1.5 million fractures annually in the United States, resulting in associated expenses of $19 billion. Furthermore, it is projected that the number of osteoporotic fractures will increase by 68% annually from 2018 to 2040, reaching 3.2 million. The rising incidence of bone fractures is expected to be a significant driver for the growth of the bone growth stimulator market.
The growth of the bone growth stimulator market is also propelled by the increasing number of sports injuries. Sports injuries, which can affect various parts of the body, including bones, muscles, ligaments, and tendons, often require interventions to aid in bone repair and rehabilitation. Bone growth stimulators play a crucial role in promoting bone restoration, tissue growth, and overall healing in sports injuries. In 2022, the National Safety Council reported a 20% increase in sports and leisure injuries in 2021 and an additional 12% increase in 2022. The growing prevalence of sports injuries is contributing to the expansion of the bone growth stimulator market.
Technological advancement is a notable trend in the bone growth stimulators market, with a focus on innovative approaches such as Electrical Bone Growth Stimulation (EBGS). This unique method aims to accelerate healing and enhance fusion success rates. The increased adoption and experience with EBGS devices have led to significant advancements in stimulation paradigms and clinical outcomes. For example, in May 2022, Orthofix Medical Inc., a U.S.-based manufacturer of spinal, orthopedic, and bone development solutions, received pre-market approval from the U.S. Food and Drug Administration (FDA) for the AccelStim bone healing therapy Class III device. The AccelStim device, utilizing Low-Intensity Pulsed Ultrasound (LIPUS), provides a nonsurgical therapy option for new fractures and fractures that are still healing (nonunions), enhancing the natural healing process of the bone.
Leading companies in the bone growth stimulator market are prioritizing innovative product approvals, as evidenced by the patent approval of the ActaStim-S Spine Fusion Bone Growth Stimulator system. This system is a non-invasive device designed to stimulate bone repair and fusion following spinal fusion surgery. Notable features include a cordless design and a user-friendly mobile app. It has received approval from the U.S. Food and Drug Administration (FDA) for use after spinal fusion procedures or to treat a failed fusion from a previous operation. In August 2022, Theragen, Inc., a U.S.-based pharmaceutical and biotechnology company, announced the successful acquisition of a U.S. patent for its groundbreaking ActaStim-S Spine Fusion Bone Growth Stimulator system. ActaStim-S is a revolutionary spine fusion stimulator, incorporating clinically proven therapeutic stimulation with modern design and a data-rich digital health platform. This approach not only enhances the healing process but also promotes patient compliance, engagement, and informed communication with healthcare practitioners during the crucial post-operative fusion phase.
In November 2022, Alleima, a company based in Sweden that produces high-value-added products in advanced stainless steels and specialty alloys, acquired ENDOSMART Gesellschaft fur Medizintechnik mbH for an undisclosed amount. This acquisition is intended to bolster Alleima's market position, broaden its product range, and enhance its capabilities in high-performance materials. ENDOSMART Gesellschaft fur Medizintechnik mbH is a German company specializing in the manufacture of medical devices and components.
Major companies operating in the bone growth stimulator market include Arthrex Inc., DJO Global Inc., Stryker Corporation, Bioventus LLC, Zimmer Biomet Holdings Inc., 3M Company, Becton Dickinson and Company, Cognionics Inc., ConMed Corporation, The Cooper Companies Inc., DyMedix Corporation, Koninklijke Philips N.V., Medtronic plc, Natus Medical Incorporated, Terumo Corporation, Orthofix Medical Inc., Ossatec Benelux BV, BTT Health GmbH, Stimulate Health Inc., ZimVie Inc., Enovis Inc., DePuy Synthes Inc., Smith & Nephew plc, BioTek Instruments Inc., BioMimetic Therapeutics Inc., Cerament, Cook Medical LLC, Curasan AG, Exactech Inc., Globus Medical Inc., Integra LifeSciences Corporation, Medartis AG, NuVasive Inc., OrthoPediatrics Corp., RTI Surgical Holdings Inc., Wright Medical Group N.V.
North America was the largest region in the bone growth stimulator market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bone growth stimulator market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
The countries covered in the bone growth stimulator market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.
The bone growth stimulator market consists of sales of electrical and ultrasound bone growth stimulator. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Bone Growth Stimulator Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on bone growth stimulator market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for bone growth stimulator ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The bone growth stimulator market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.